Answers are grounded in this paper and cite their sources.
This review examines new strategies for creating selective therapeutic conjugates in oncology, suggesting significant advancements in targeting abilities.
This review provides a systematic analysis of modern strategies for developing highly selective therapeutic conjugates for oncology. It examines the evolution from first-generation antibody-drug conjugates (ADCs) to advanced next-generation platforms. The focus is on key conjugate components: targeting modules (bispecific antibodies, small scaffold proteins — affibodies, DARPins, adnectins), linker systems with controlled release, and an expanding arsenal of cytotoxic and cytomodulatory payloads. Special attention is given to innovative technologies, such as PROTAC-ADCs, oligonucleotide conjugates, and photoimmunoconjugates, which enable targeting of "undruggable" molecules and manipulation of intracellular processes. Strategies for site-specific conjugation to obtain homogeneous preparations are analyzed. The conclusion is drawn that the convergence of refined components and novel platforms shapes the future of targeted therapy, aimed significantly at enhancing the therapeutic index and overcoming drug resistance.
No takes yet. Share an insight, caveat, or question.
Shulcheva et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: